Medical Marijuana, Inc. Announces Results of Annual Meeting and Second Adjournment to Solicit Additional Votes
SAN DIEGO, Dec. 13, 2018
SAN DIEGO, Dec. 13, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, held its Annual Meeting of Shareholders on November 30, 2018 which was adjourned to December 3, 2018 due to a lack of quorum.
At the re-convened meeting on December 3, 2018, a quorum was met and all five directors of MJNA were reelected to staggered terms. A second proposal, however, still lacks the votes needed for approval. Accordingly, the Annual Meeting of Shareholders was adjourned indefinitely for a second time solely as it relates to the second proposal. This proposal is only approximately 1% short of the vote needed for approval.
Voting remains open. MJNA management urges its shareholders of record at close of business as of November 12, 2018 to vote their shares "FOR" the second proposal.
The matters to be voted on at the meeting, and the method to do so via online, mail or telephone vote are set forth in the Notice of Meeting and Proxy Statement previously sent to its shareholders.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
SOURCE Medical Marijuana, Inc.